Predictive Value of Circulating Renalase for Left Ventricular Hypertrophy in Non-Dialysis CKD Patients
Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) · 01.05.2026 · 10 (2) · 192-201
DOI: 10.54133/ajms.v10i2.2721 ↗Kurz gefasst
Fachartikel in der Zeitschrift Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ), online erschienen am 01.05.2026. Verfasst von Karrar Mohammed Abbas und 2 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) is a global health burden strongly associated with cardiovascular morbidity and mortality. Left ventricular hypertrophy (LVH), a hallmark of cardiac remodeling in CKD, is a major predictor of heart failure and sudden cardiac death. Current biomarkers fail to capture early remodeling risk adequately, underscoring the need for novel predictors.
Objective
To evaluate serum renalase levels in non-dialysis CKD patients (stages 3–5) and determine its predictive value for cardiac remodeling, particularly LVH.
Methods
A cross-sectional study was conducted, including 89 CKD patients, 40 heart failure patients, and 37 healthy controls. Demographic, clinical, biochemical, and echocardiographic data were collected. Serum renalase was measured using ELISA. Logistic regression models and receiver operating characteristic (ROC) analyses were applied to assess the independent predictive value of renalase for cardiac remodeling.
Results
CKD patients with cardiac remodeling had significantly higher renalase levels compared to those without (36.31ng/mL vs. 33.05ng/mL, p=0.009). ROC analysis yielded an AUC of 0.656, with a cutoff value of >37.64 ng/mL (sensitivity, 47.5%; specificity, 83.3%). Logistic regression confirmed renalase as an independent predictor of remodeling (adjusted OR: 1.105, 95% CI=1.036–1.178, p=0.002), alongside uncontrolled hypertension (OR=3.462, p=0.014).
Conclusions
Serum renalase is independently associated with LVH in non-dialysis CKD patients and demonstrates moderate discriminative ability with high specificity. These findings highlight renalase as a promising biomarker for early cardiac risk stratification in CKD, warranting further longitudinal validation and standardization of measurement protocols.
Zitieren
APA
Abbas, K. M., Mohammed, M. M., & Hamas, M. A. A. (2026). Predictive Value of Circulating Renalase for Left Ventricular Hypertrophy in Non-Dialysis CKD Patients. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ), 10(2), 192-201. https://doi.org/10.54133/ajms.v10i2.2721
Vancouver
Abbas KM, Mohammed MM, Hamas MAA. Predictive Value of Circulating Renalase for Left Ventricular Hypertrophy in Non-Dialysis CKD Patients. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ). 2026;10(2):192-201. doi:10.54133/ajms.v10i2.2721
BibTeX
@article{Abbas2026,
author = {Abbas, Karrar Mohammed and Mohammed, Mohammed Mahmmod and Hamas, Mohammed Abdel Alhassan},
title = {Predictive Value of Circulating Renalase for Left Ventricular Hypertrophy in Non-Dialysis CKD Patients},
journal = {Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )},
year = {2026},
volume = {10},
number = {2},
pages = {192--201},
doi = {10.54133/ajms.v10i2.2721}
}
EUVIMED